¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"synthetic messenger RNA"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • RNA
    ¸®º¸ÇÙ»ê, RNA
  • RNA splicing
    RNA½ºÇöóÀ̽Ì, ¸®º¸ÇÙ»êÀß¶óÀÌÀ½
  • RNA virus
    RNA¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ribosomal RNA
    ¸®º¸¼Ø¾Ë¿£¿¡ÀÌ
  • RNA splicing
    ¾Ë¿£¿¡ÀÌÂ¥±é±â, ¸®º¸ÇÙ»êÂ¥Áý±â
  • RNA virus
    ¾Ë¿£¿¡À̹ÙÀÌ·¯½º
  • transfer RNA
    Àü´Þ¾Ë¿£¿¡ÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • RNA virus
    RNA ¹ÙÀÌ·¯½º
  • RNA, ribosomal
    ¸®º¸¼Ø RNA, rRNA
  • RNA, transfer
    Àü´ÞRNA, tRNA
  • RNA-dependent DNA polymerase
    RNA-ÀÇÁ¸ DNA ÁßÇÕÈ¿¼Ò
  • RNA=£¾ribonucleic acid
    ¸®º¸ÇÙ»ê.
  • hybridization, DNA-RNA
    DNA-RNA ¦Áö¿ì±â, DNA-RNA ºÎÇÕÈ­(~ݬùêûù)
  • immunogen RNA
    ¸é¿ª¿ø¼º RNA.
  • positive strand RNA
    ¾ç¼º°¡´Ú RNA
  • pseudoknot RNA structure
    ¸ÅµìÇü RNA ±¸Á¶
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • synthetic analgesic drug
    ÇÕ¼ºÁøÅëÁ¦.
  • synthetic antigen
    ÇÕ¼ºÇ׿ø(¡­ù÷ê«).
  • synthetic chemistry
    ÇÕ¼ºÈ­ÇÐ(ùêà÷ûùùÊ).
  • synthetic detergent
    ÇÕ¼º¼¼Á¦(ÊÙËÛÌ¡).
  • synthetic drug
    ÇÕ¼º¾à(ùêà÷å·).
  • synthetic fiber
    ÇÕ¼º¼¶À¯
  • synthetic medium
    ÇÕ¼º¹èÁö(ùêà÷ÛÆò¢).
  • synthetic resin
    ÇÕ¼º¼öÁö(¡­â§ò·).
  • synthetic rubber
    ÇÕ¼º°í¹«.
  • synthetic sludge
    ÇÕ¼º½½·¯Áö. ÇÕ¼º¿À´Ï(̰ËÛ ËçËö).
  • synthetic vaccine
    ÇÕ¼º¹é½Å
  • synthetic vascular graft
    ÇÕ¼ºÇ÷°ü(¡­úìη), ´ë¿ëÇ÷°ü(ÓÛéÄúìη).
  • histydyl-t-rna synthetase
    Histydyl-t-RNA ÇÕ¼ºÈ¿¼Ò
  • hybridization, DNA-RNA
    DNA-RNA ¦Áö¿ì±â, DNA-RNA ºÎÇÕÈ­(~ݬùêûù)
  • immunogen RNA
    ¸é¿ª¿ø¼º RNA.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • messenger ribonucleoprotein particle
    Àü·É(îîÖµ) ¸®º¸ÇÙ»ê(ß«)´Ü¹éÁú ÀÔÀÚ(Ó±ÛÜòõØ£í­)
  • messenger ribonucleoproteins
    Àü·É(îîÖµ) ¸®º¸ÇÙ»ê´Ü¹éÁú(ú·ß«Ó±ÛÜòõ)
  • polygenic messenger
    ´ÙÀ¯ÀüÀÚ Àü·É(Òýë¶îîí­îîÖµ)
  • primary messenger
    ÀÏÂ÷ Àü·É(ìéó­îîÖµ)
  • secondary messenger
    ÀÌÂ÷ Àü·É (ì£ó­îîÖµ)
  • second messenger
    Á¦(ð¯) 2 Àü·É (îîÖµ)
  • two-messenger hypothesis
    ÀÌ(ì£)Àü·É(îîÖµ)¼³(àã)
  • acceptor RNA
    ¼ö¿ë(â¥é»)RNA
  • adapter RNA
    ¾Æ´äÅÍ RNA
  • adaptor RNA
    ¾Æ´äÅÍ RNA
  • amino acid accepting RNA
    ¾Æ¹Ì³ë»ê(ß«) ¼ö³³(áôÒ¡)RNA
  • chromosomal RNA
    ¿°»öü(æøßäô÷) RNA
  • complementary RNA
    »óº¸¼º(ßÓÜÍàõ) RNA
  • complex RNA
    º¹ÇÕ(ÜÜùê) RNA
  • DNA-dependent RNA polymerase
    DNAÀÇÁ¸ RNA Æú¸®¸Ó·¹À̽º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
H-mRNA H-chain messenger ribonucleic acid
HSR Harleco synthetic resin; heated serum reagin; homogeneously staining region
mRNA messenger ribonucleic acid
mRNP messenger ribonucleoprotein
pre-mRNA precursor messenger ribonucleic acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
hn-RNA Heteronuclear RNA
I-RNA Immune RNA
poly(A)+ RNA Polyadenylated RNA
RDRP RNA dependent RNA polymerase
sat RNA satellite RNA
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
prostaglandin endoperoxides, synthetic Synthetic compounds that are analogs of the naturally occurring prostaglandin endoperoxides and that mimic their pharmacologic and physiologic activities. They are usually more stable than the naturally occurring compounds.
(12 Dec 1998)
prostaglandins a, synthetic Analogs or derivatives of prostaglandin a that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pga.
(12 Dec 1998)
prostaglandins e, synthetic Analogs or derivatives of prostaglandins e that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pge.
(12 Dec 1998)
prostaglandins f, synthetic Analogs or derivatives of prostaglandins f that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pgf.
(12 Dec 1998)
prostaglandins, synthetic Compounds obtained by chemical synthesis that are analogs or derivatives of naturally occurring prostaglandins and that have similar activity.
(12 Dec 1998)
hormones, synthetic Synthetic chemical compounds that mimic the activity of hormones produced in the body, but differ in structure from naturally occurring hormones.
(12 Dec 1998)
synthetic Relating to or made by synthesis.
(05 Mar 2000)
synthetic chemistry The formation or building up of complex compounds by uniting the more simple ones.
(05 Mar 2000)
synthetic dyes Organic dye compounds originally derived from coal-tar derivatives; presently produced by synthesis from benzene and its derivatives; examples include eosin, methylene blue, and fluorescein.
(05 Mar 2000)
oestrogens, synthetic Compounds obtained by chemical synthesis which possess oestrogenic activity, but differ in structure from naturally occurring oestrogens.
(12 Dec 1998)
acceptor RNA rNA
antisense RNA <molecular biology> A complementary RNA sequence that binds to (and thus blocks the transcription of) a naturally-occuring (sense) messenger RNA molecule.
These proteins can be used to selectively turn off production of certain proteins or block viral genetic instructions, by marking them for destruction by cellular enzymes, in order to prevent the building of new virus or the infection of new cells.
(09 Oct 1997)
bacteriophage T3 RNA polymerase <enzyme> Used for the rapid generation of strand-specific RNA molecules that can be used for the identification of genes in hybridization experiments
Registry number: EC 2.7.7.-
Synonym: t3 RNA polymerase
(26 Jun 1999)
cap II RNA(nucleoside-2'-)methyltransferase <enzyme> Converts cap i-terminated mRNA to cap II-terminated mRNA
Registry number: EC 2.1.1.-
Synonym: cap II methylase
(26 Jun 1999)
cap I RNA (nucleoside-2'-)methyltransferase <enzyme> Converts cap 0-terminated mRNA to cap i-terminated mRNA
Registry number: EC 2.1.1.-
Synonym: cap I methylase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á